There are several biological agents approved globally to treat both Crohn’s disease (CD) and ulcerative colitis (UC), with different mechanisms of action: tumor-necrosis factor (TNF) inhibitors, anti-integrins, and anti-interleukins [4,5]. This evidence concerns the gene TNF and Crohn disease.